In a report released in November 2017, the World Health Organization (WHO) estimated that "1 in 10 medical products circulating in low and middle-income countries is either substandard or falsified;" that includes pills, vaccines, and diagnostic kits that also impacting the U.S. health system. The counterfeit drug problem is not new but has been growing exponentially worldwide. The internet has facilitated the trafficking of fake and substandard drugs worldwide and drug shortages have accelerated the problem in the United States. Falsified and poor-quality drugs may be purchased online or in street markets, however, in developing countries, the supply chain may stretch between several countries, using ingredients from one area, manufactured in another, packaged in a third country and distributed in a fourth.Addressing this issue includes identification of diversion/insertion points, following the API, examining import/export records and harnessing social media information.
Discuss the worldwide problem of counterfeit and fake pharmaceuticals and devices
Identify strategies that address the intersection of cost, quality and outcomes in the pharmaceutical supply chain
Integrate best practices of replicable supply chain strategies that address the use of data analytics
Construct and streamline supplier relationships to promote risk sharing
Differentiate redesign structures that support a continuum of care which manages quality and costs